Kiniksa Pharmaceuticals International (KNSA) Work In Process (2021 - 2023)

Kiniksa Pharmaceuticals International has reported Work In Process for 3 years, with the latest figure at $18.3 million in Q4 2023.

• For the quarter ending Q4 2023, Work In Process rose 189.26% year-over-year to $18.3 million; the trailing twelve-month figure through Dec 2023 stood at $18.3 million (up 189.26% YoY), and the FY2023 full-year result was $18.3 million, up 189.26% from the prior year.
• Work In Process for Q4 2023 stood at $18.3 million, up from $13.4 million in the prior quarter.
• The five-year high for Work In Process was $18.3 million in Q4 2023, with the low at $148000.0 in Q1 2022.
• Historically, Work In Process has averaged $8.3 million across 3 years, with a median of $6.5 million in 2022.
• The largest YoY upside for Work In Process was 9033.11% in 2023 against a maximum downside of 189.26% in 2023.
• Kiniksa Pharmaceuticals International's Work In Process stood at $4.2 million in 2021, then soared by 50.9% to $6.3 million in 2022, then soared by 189.26% to $18.3 million in 2023.
• The last three Work In Process figures came in at $18.3 million (Q4 2023), $13.4 million (Q3 2023), and $6.6 million (Q2 2023), per Business Quant data.